| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
Phase 1 Readout example | Phase 1 | — | Subscribe to access the data. | Biologics | Dermatologic System | ||
Phase 1 Readout example | Phase 1 | — | Subscribe to access the data. | Biologics | Dermatologic System | ||
Phase 1 Readout example | Phase 1 | — | Subscribe to access the data. | Biologics | Dermatologic System |
Recent Updates
Recently added Catalysts
Oruka Therapeutics, Inc.$86.79
-1.48 (-1.68%)
C 50Pipeline Score Overvalued Pharma · Clinical
Market Cap
3.66 B
EPS
-2.39
P/E Ratio
-
Value Trade
47.10 M
SEC Financials
Q1 2026Dilution Risk
R&D Expenses
29.14 M
Operating CF
-23.58 M
Total Assets
504.48 M
Total Liabilities
17.76 M
Equity
486.72 M
D/E Ratio
12,345
-3.02 %
Week
-13.18 %
1 Month
87.94 %
3 Month
125.32 %
6 Month
-87.51 %
5 Year
-100 %
All Time
Cash Data
Cash Position
388.83 M
Monthly Burn
7.86 M
Runway
47.5 mo
Burn Trend
StableSEC Filing
May 13, 2026
Overview
Volume
503.02 K
52 Week Range
10.64 - 91
% held by Insiders
15.77 %
% held by Institutions
76.5 %
Enterprise Value
3.27 B
Total Shares
60.29 M
Short %
24.95 %
Float Shares
36.72 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for Oruka Therapeutics, Inc.
374Total events
6Upcoming
67Tier-1 (high impact)
2009 – 2027Coverage
Upcoming catalysts 6
Event history 368
Q3 2026
◆Trial InitiationORKA-002Trial
Phase 2 trial in HS expected to initiate in 2H 2026
hidradenitis suppurativasource ↗
Q3 2026
◆Topline ReadoutORKA-001 Induction DoseClinical Data
Efficacy and response duration data from ORKA-001 Phase 2a expected in 2H 2026
moderate-to-severe psoriasissource ↗
Jun 3, 2026
May 2026
▲Partnership / LicenseORKA-001 Induction DoseCorporate
Collaboration and license agreement with Halozyme for Hypercon technology
psoriatic diseasesource ↗
Apr 28, 2026
▼Equity OfferingCorporate
Pricing of upsized $700 million underwritten public offering of 9,660,000 shares at $72.50 per share
Apr 27, 2026
▼Equity OfferingCorporate
Proposed $500 million underwritten public offering of common stock and pre-funded warrants
Apr 27, 2026
◆Topline ReadoutORKA-001 Induction DoseClinical Data
Week 16 data for ORKA-001 from EVERLAST-A trial
moderate-to-severe plaque psoriasissource ↗
Apr 27, 2026
●Oral PresentationORKA-001 Induction DosePresentation
Webcast of EVERLAST-A results
moderate-to-severe plaque psoriasissource ↗
Q2 2026
◆Timing GuidanceORKA-001 Induction DosePresentation
Longer-term EVERLAST-A data expected in 2H 2026
moderate-to-severe plaque psoriasissource ↗
Q2 2026
◆Topline ReadoutORKA-001 Induction DoseClinical Data
Efficacy and response duration data from EVERLAST-A expected
moderate-to-severe psoriasissource ↗
Q2 2026
Drug Pipeline Intelligence
C50
Pipeline Score $1.6B
Pipeline ValueOvervalued
Valuation Signal2
Drugs Scored0.4x
rNPV / MCap Top 75%
Small Cap (rank 229 of 912)
Percentile RankOruka Therapeutics, Inc. carries a moderate pipeline score (50/100), with $2.5B risk-adjusted pipeline value, led by ORKA-001 Induction Dose in Plaque Psoriasis (Phase 2).
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ORKA-002 Small molecule | Plaque Psoriasis | Phase 2 | NCT07474792 | 17% | $1.2B | RECRUITING | 160 | VERY_FAST | B (66) | Apr 1, 2029 | LOW_RISK | LOW Jul 9, 2026 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
ORKA-001 | moderate-to-severe plaque psoriasis | Phase 2a | 2026-04-27 | PASI 100: 63.5% (40/63); PASI 90: 83%; IGA 0/1: 84%; placebo PASI 100: 1 of 21 Read More | Oruka Therapeutics Announces Positive Week 16 Data for ORKA-001 from the Ongoing EVERLAST-A Phase 2a Trial in Moderate-to-Severe Plaque Psoriasis Read More | |
ORKA-001 | moderate-to-severe plaque psoriasis | Phase 2a | 2026-04-27 | PASI 100: 63.5% (40/63); PASI 90: 83%; IGA 0/1: 84%; placebo PASI 100: 1 of 21 Read More | Oruka Therapeutics Announces Positive Week 16 Data for ORKA-001 from the Ongoing EVERLAST-A Phase 2a Trial in Moderate-to-Severe Plaque Psoriasis Read More | |
ORKA-001 | moderate-to-severe plaque psoriasis | Phase 2a | 2026-04-27 | PASI 100: 63.5% (40/63); PASI 90: 83%; IGA 0/1: 84%; placebo PASI 100: 1 of 21 Read More | Oruka Therapeutics Announces Positive Week 16 Data for ORKA-001 from the Ongoing EVERLAST-A Phase 2a Trial in Moderate-to-Severe Plaque Psoriasis Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in ORKA
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
ORKA Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2027-03-19 | 0.00 | 0 | - | - | - | - | - | - | ||||
| 2027-03-19 | 0.00 | 0 | - | - | - | - | - | - | ||||
| 2027-03-19 | 0.00 | 0 | - | - | - | - | - | - | ||||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
ORKAOruka Therapeutics to Present at the 2026 Jefferies Global Healthcare Conference
Oruka Therapeutics will present at the 2026 Jefferies Global Healthcare Conference in New York on June 3rd. The company focuses on developing novel biologics for chronic skin diseases, including plaque psoriasis. Their goal is to provide effective treatments with infrequent dosing schedules, enhancing patient quality of life.
Read more →ORKAOruka Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update
Oruka Therapeutics has reported its first-quarter 2026 financial results alongside significant updates on its drug pipeline. Data from the EVERLAST-A trial showed a PASI 100 rate of 63.5% for its lead candidate, ORKA-001, which is well-tolerated. The company also initiated a Phase 2 trial for ORKA-002 and detailed a solid financial position, projecting sufficient funds through its upcoming BLA filing for ORKA-001. Future data releases are anticipated in 2026 and 2027, which may further influence their market standing.
Read more →ORKARecent Developments Certain Financial and Operating Data for First Quarter 2026 While we have not finalized our full financial results for the quarter ended
The article discusses the preliminary financial data for ORKA for the first quarter of 2026, highlighting an estimated cash, cash equivalents, and investments totaling approximately $496 million as of March 31, 2026. It underscores that these figures are not yet finalized and are subject to revision based on the closing of accounting records. The report emphasizes that the data has not been audited or reviewed by PricewaterhouseCoopers LLP, indicating a need for caution in relying on this preliminary estimate.
Read more →ORKAOruka Therapeutics Announces Pricing of Upsized $700 Million Underwritten Public Offering
Oruka Therapeutics has announced the pricing of its upsized public offering, raising approximately $700.4 million by selling 9,660,000 shares at $72.50 each. The offering is set to close around April 30, 2026, pending customary conditions. The funds will aid in advancing Oruka's monoclonal antibody therapeutics for chronic skin diseases.
Read more →ORKA▲ +10.7%on this newsshared move
Oruka Therapeutics Announces Positive Week 16 Data for ORKA-001 from the Ongoing EVERLAST-A Phase 2a Trial in Moderate-to-Severe Plaque Psoriasis
Oruka Therapeutics announced positive interim results from the EVERLAST-A Phase 2a trial of ORKA-001 for moderate-to-severe plaque psoriasis. The trial showed that 63.5% of participants achieved complete skin clearance at Week 16. The safety profile was favorable, with no serious adverse events reported. Future data updates are expected in 2026.
Read more →ORKA▲ +10.7%on this newsshared move
Oruka Therapeutics Announces Proposed $500 Million Underwritten Public Offering
Oruka Therapeutics has announced a proposed underwritten public offering of $500 million in common stock, with an additional option for underwriters to purchase up to $75 million more. The offering is intended to support the company's development of novel monoclonal antibody therapeutics for psoriasis and other inflammatory conditions. However, the completion of the offering is contingent on market conditions.
Read more →ORKA▲ +10.7%on this newsshared move
Oruka Therapeutics to Host Conference Call to Report Week 16 Data for ORKA-001 from the Ongoing EVERLAST-A Trial on April 27, 2026
Oruka Therapeutics will report Week 16 data for ORKA-001 from the EVERLAST-A Phase 2a trial on April 27, 2026. The trial focuses on moderate-to-severe plaque psoriasis. Following the data release, a conference call will be held to discuss the results. The company aims to set a new standard in treating chronic skin diseases.
Read more →ORKA▲ +25%on this news
Oruka Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update
Oruka Therapeutics reported its financial results for Q4 and full year 2025, highlighting a strong cash position of $479.6 million. The company announced the completion of enrollment for its EVERLAST-A trial and the initiation of the ORKA-002 Phase 2 trial for psoriasis. However, it also noted an increase in net loss and R&D expenses.
Read more →ORKAOruka Therapeutics to Participate in Multiple Upcoming Conferences
Oruka Therapeutics, a clinical-stage biotechnology company, announced its participation in several upcoming conferences, including the Guggenheim Emerging Outlook: Biotech Summit and the TD Cowen Annual Health Care Conference. The company is focused on developing novel biologics for chronic skin diseases, particularly plaque psoriasis, aiming to provide patients with effective treatment options. Presentations will be available via webcast on their investor events website.
Read more →ORKA▲ +10.2%on this news
Oruka Therapeutics Announces Positive Interim Phase 1 Data for ORKA-002 and Initiation of EVERLAST-B Trial of ORKA-001
Oruka Therapeutics has announced positive interim Phase 1 data for ORKA-002, indicating a long half-life that could allow for less frequent dosing in treating psoriasis and hidradenitis suppurativa. The company plans to initiate Phase 2 trials for ORKA-002 in 2026 and reports ongoing advancement in the EVERLAST-B Phase 2b trial for ORKA-001, with data expected in 2027. CEO Lawrence Klein expressed confidence in the emerging product profiles of both assets and their potential role in treating chronic skin diseases. Safety outcomes from ORKA-002 trials have been favorable, helping to bolster expectations for future development.
Read more →ORKAOruka Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference
Oruka Therapeutics, a clinical stage biotechnology company focused on chronic skin disease treatments, will present at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco from January 12-15, 2026. The company aims to improve treatment for plaque psoriasis, highlighting its commitment to developing novel biologics. A webcast of the presentation will be available online for investors and stakeholders.
Read more →ORKAOruka Therapeutics Announces New Board Member and Board Transition
Oruka Therapeutics has announced the appointment of Chris Martin to its Board of Directors, highlighting his considerable commercial experience. This transition coincides with the resignation of Cameron Turtle, who has contributed significantly to the company's early strategy. The CEO expressed optimism about Martin's ability to advance the company's late-stage development efforts, particularly regarding products ORKA-001 and ORKA-002. Oruka is focused on developing innovative biologics for chronic skin diseases, including plaque psoriasis.
Read more →ORKA▼ -6.8%on this news
Oruka Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update
Oruka Therapeutics reported strong financial results for Q3 2025, highlighting promising data from its ORKA-001 Phase 1 trial. The company has over $500 million in cash, ensuring a runway beyond key upcoming clinical readouts. ORKA-001 is showing potential for effective treatment with less frequent dosing, while the ORKA-002 Phase 1 trial is ongoing.
Read more →ORKAOruka Therapeutics to Present at Multiple November Investor Conferences
Oruka Therapeutics, a clinical-stage biotechnology firm, has announced its participation in several investor conferences in November 2025. These include the Guggenheim 2nd Annual Healthcare Innovation Conference, the Stifel 2025 Healthcare Conference, and the Jefferies Global Healthcare Conference. The company is focused on developing biologics for chronic skin diseases such as plaque psoriasis.
Read more →ORKA▲ +8.8%on this news
Oruka Therapeutics Announces $180 Million Private Placement
Oruka Therapeutics has announced a $180 million private placement to support its operations and research. The financing, led by Viking Global Investors, involves the sale of over 10 million shares at $15 each. The company plans to use the proceeds for R&D and general corporate expenses, ensuring operational funding for at least one year post Phase 2 trial data readouts.
Read more →ORKA▲ +8.8%on this newsshared move
Oruka Therapeutics Announces Positive Interim Phase 1 Results for ORKA-001
Oruka Therapeutics has announced positive interim results from its Phase 1 trial of ORKA-001, a long-acting IL-23p19 antibody for plaque psoriasis. The drug's promising 100-day half-life may allow for once-per-year dosing, with ongoing trials aiming to demonstrate higher efficacy and extended off-treatment remissions. Initial data from the subsequent Phase 2a trial is expected in the second half of 2026.
Read more →ORKAOruka Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update
Oruka Therapeutics has reported its financial results for the second quarter of 2025 and provided an update on its clinical trials. The company has initiated the EVERLAST-A Phase 2a trial for its treatment ORKA-001, aiming to distinguish it from existing IL-23 inhibitors. Financially, Oruka holds $351.5 million in cash, but has reported a net loss of $24.6 million, with increasing R&D expenses. Future presentations of trial data are scheduled for EADV in September 2025, with more significant results expected in 2026.
Read more →ORKA▼ -5.3%on this news
Oruka Therapeutics Announces IND Clearance for EVERLAST-A Phase 2a Trial of ORKA-001 in Psoriasis with Phase 1 Data to be Presented at EADV in September
Oruka Therapeutics has received FDA clearance for its Phase 2a trial of ORKA-001, targeting moderate-to-severe psoriasis. The trial, named EVERLAST-A, will assess the safety and efficacy of ORKA-001, a long-acting anti-IL-23p19 antibody. Initial data from the trial is expected in the second half of 2026, with further details to be presented at the EADV Congress in September.
Read more →ORKA▲ +6.9%on this news
Oruka Therapeutics Announces Promotion of Laura Sandler to Chief Operating Officer
Oruka Therapeutics has promoted Laura Sandler to Chief Operating Officer, recognizing her extensive experience in biopharmaceutical leadership. Sandler, who previously served as SVP of Operations, has been instrumental in advancing Oruka's clinical programs. The company focuses on developing novel biologics for chronic skin conditions, particularly plaque psoriasis, with an emphasis on effective treatment strategies.
Read more →ORKAOruka Therapeutics to Present at the Jefferies Global Healthcare Conference
Oruka Therapeutics will present at the Jefferies Global Healthcare Conference on June 4, 2025. The company focuses on developing novel biologics for chronic skin diseases, including plaque psoriasis. Their goal is to provide effective treatments with minimal dosing frequency. A webcast of the presentation will be available online.
Read more →ORKAOruka Therapeutics Announces First Participants Dosed in Phase 1 Trial of ORKA-002, its Novel Half-life Extended Anti-IL-17A/F Antibody
Oruka Therapeutics has commenced dosing in its Phase 1 trial for ORKA-002, a novel monoclonal antibody targeting IL-17A/F. The trial aims to assess safety and pharmacokinetics in healthy volunteers, with interim data expected by the end of 2025. ORKA-002 could potentially offer a dosing regimen of two to three times a year, significantly improving treatment options for psoriasis and related conditions.
Read more →ORKAOruka Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update
Oruka Therapeutics has reported its first quarter 2025 financial results and highlighted significant progress in its clinical pipeline, particularly for its lead programs ORKA-001 and ORKA-002 targeting psoriasis. The company has completed dosing for ORKA-001's Phase 1 trial and anticipates initial data release by 3Q 2025, with Phase 2a initiation planned for 2H 2025. The financial results show a robust cash position of $373 million providing a runway through 2027, despite reporting a net loss of $21 million in the quarter. The company is focused on innovative treatment solutions for chronic skin diseases, aiming to set new standards in patient outcomes.
Read more →ORKAOruka Therapeutics to Present at Bank of America Securities 2025 Health Care Conference
Oruka Therapeutics, a clinical stage biotechnology company focused on chronic skin disease treatments, will present at the Bank of America Securities 2025 Health Care Conference on May 13, 2025. The company's mission is to provide patients with improved options for conditions like plaque psoriasis through infrequent dosing and innovative biologics. Their proprietary antibodies target core mechanisms of plaque psoriasis and related inflammatory diseases, setting a new standard in treatment.
Read more →ORKAOruka Therapeutics Announces Preclinical Data for ORKA-002 at the 2025 American Academy of Dermatology Annual Meeting
Oruka Therapeutics has presented promising preclinical data for ORKA-002, a monoclonal antibody targeting IL-17A/F, at the 2025 American Academy of Dermatology Annual Meeting. The data suggests that ORKA-002 has a significantly extended half-life compared to bimekizumab, potentially enabling infrequent dosing every four to six months. With equivalent potency to existing therapies, ORKA-002 is positioned to set a new standard in the treatment of chronic skin diseases like plaque psoriasis. The first human doses are expected to begin in Q3 2025, marking a significant milestone for the company's development pipeline.
Read more →ORKAOruka Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update
Oruka Therapeutics has reported its fourth quarter and full year 2024 financial results, marking significant advancements in its clinical pipeline. The company has initiated the Phase 1 trial of its lead candidate, ORKA-001, with interim data expected in late 2025, while plans for a Phase 2a study are set for the same year. Following a successful public transaction, Oruka has raised over $475 million, ensuring funding through 2027. Additionally, a Phase 1 trial for ORKA-002 is scheduled to begin in Q3 2025, highlighting Oruka's strategy to introduce innovative treatment options for chronic skin diseases.
Read more →ORKAOruka Therapeutics to Present at Multiple March Investor Conferences
Oruka Therapeutics, a clinical stage biotechnology firm, is set to present at several investor conferences in March 2025, including TD Cowen's 45th Annual Health Care Conference and the Leerink Global Healthcare Conference. The company is developing novel biologics aimed at treating chronic skin diseases such as plaque psoriasis. Their goal is to achieve significant disease clearance for patients with less frequent dosing schedules. The presentations signify Oruka's commitment to engaging with investors and sharing updates on its product advancements.
Read more →ORKAOruka Therapeutics Announces First Participants Dosed in Phase 1 Trial of ORKA-001, its Novel Half-life Extended Anti-IL-23p19 Antibody
Oruka Therapeutics has commenced dosing healthy volunteers in a Phase 1 trial for its novel anti-IL-23p19 antibody, ORKA-001. The trial aims to evaluate the safety, tolerability, and pharmacokinetics of the drug, with data expected by late 2025. If successful, a follow-up proof-of-concept study in moderate-to-severe psoriasis is planned for the same timeframe, which may offer promising new treatment options with less frequent dosing. The company has also secured a license agreement with Paragon Therapeutics for ORKA-001 in most indications.
Read more →ORKAOruka Therapeutics to be Added to the Nasdaq Biotechnology Index (NBI)
Oruka Therapeutics, a biotechnology company focused on chronic skin diseases, has announced it will be added to the Nasdaq Biotechnology Index, effective December 23, 2024. This addition showcases the company's commitment to develop innovative biologics for conditions such as plaque psoriasis. Oruka aims to enhance patient care through its proprietary antibodies, which target mechanisms of skin diseases. The Nasdaq Biotechnology Index tracks biotechnology and pharmaceutical firms meeting specific eligibility criteria.
Read more →ORKA▲ +5.5%on this news
Oruka Therapeutics to Present at Piper Sandler’s 36th Annual Healthcare Conference
Oruka Therapeutics, Inc. (Nasdaq: ORKA) announced its participation in Piper Sandler’s 36th Annual Healthcare Conference, scheduled for December 3rd, 2024. The company is focused on developing novel biologics aimed at treating chronic skin diseases, including plaque psoriasis. Oruka's mission emphasizes achieving high rates of disease clearance with minimal dosing frequency, reflecting its commitment to improving patient outcomes.
Read more →ORKA▼ -6.4%on this newsshared move
REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM To the Board of Directors and Stockholders of Oruka Therapeutics, Inc. Opinion on the Financial Statement - Balance Sheet We have audited the accompanying balance s
Oruka Therapeutics, Inc. recently released its financial statement, which revealed that as of February 6, 2024, the company has neither generated revenue nor achieved any sales from its product candidates. The report indicates substantial doubt regarding Oruka's ability to sustain operations in the long term, due primarily to consistent financial losses and a lack of cash flow. Management's plans to address these challenges were mentioned in the accompanying notes, though the financial statement does not account for potential adjustments arising from uncertainties about its viability.
Read more →ORKAOruka Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update
Oruka Therapeutics, Inc. reported strong third quarter financial results, marking a significant milestone with a successful go-public transaction that raised over $475 million. The company plans to accelerate its clinical trials for ORKA-001 and ORKA-002, potential treatments for chronic skin diseases, with the first human trial of ORKA-001 set for early 2025. Promising data on the pharmacokinetics of ORKA-001, presented at the EADV conference, suggest its half-life and efficacy may surpass existing therapies. Overall, Oruka's financial health and promising pipeline position it well for future growth.
Read more →ORKAOruka Therapeutics Announces Preclinical Data for ORKA-001 at the European Academy of Dermatology and Venereology Congress
Oruka Therapeutics has announced promising preclinical data for ORKA-001, a monoclonal antibody targeting IL-23p19. The data presented at the EADV Congress indicates that ORKA-001 has a half-life significantly longer than risankizumab, suggesting the potential for less frequent dosing, possibly once or twice a year. The binding affinity and functional potency of ORKA-001 are comparable to risankizumab, reinforcing its potential efficacy. This advancement aligns with Oruka's mission to enhance treatment options for chronic skin diseases like plaque psoriasis.
Read more →ORKA▼ -12.2%on this news
Oruka Therapeutics Announces Accelerated Clinical Timelines and Upcoming Presentation at EADV Supporting ORKA-001’s Profile as a Potentially Best-in-Class Half-Life Extended Antibody Targeting IL-23p19
Oruka Therapeutics has announced progress on its clinical pipeline, particularly for ORKA-001 and ORKA-002, both aimed at treating chronic skin diseases. ORKA-001's first-in-human dosing is now anticipated in early 2025, showing promising preclinical results with a prolonged half-life. Upcoming data will also be presented at the EADV Congress in Amsterdam this September, highlighting ORKA-001’s potential advantages over existing therapies. Both drug candidates are designed to minimize dosing frequency while maximizing efficacy in chronic skin conditions such as psoriasis.
Read more →ORKA▼ -12.2%on this news
Oruka Therapeutics Announces $200 Million Private Placement
Oruka Therapeutics has announced a successful $200 million private placement aimed at enhancing its operations and funding research and development efforts focused on chronic skin diseases. The financing involves the sale of common stock and preferred shares, with notable participation from several investment firms. This significant capital injection is expected to support Oruka's plan through 2027, underscoring investor confidence in its innovative pipeline targeting conditions like plaque psoriasis.
Read more →ORKAOruka Therapeutics Announces Closing of Merger with ARCA biopharma and Previously Announced Private Placement of $275 Million Oruka is advancing a pipeline of potentially best-in-class biologics that aim to offer greater
Oruka Therapeutics has successfully merged with ARCA biopharma and secured $275 million in private placement funding. The merger aims to advance Oruka’s promising drug pipeline, particularly the candidates ORKA-001 and ORKA-002, both targeting chronic skin diseases like plaque psoriasis. Samarth Kulkarni has been appointed as Chairman of Oruka's Board of Directors. The company is poised to begin trading on Nasdaq under the ticker symbol 'ORKA'.
Read more →ORKAARCA biopharma Provides Update Regarding Special Dividend Amount in Connection with the Proposed Merger with Oruka Therapeutics Westminster, CO
ARCA biopharma has provided an update regarding its upcoming special cash dividend of $1.613 per share, which is associated with the proposed merger with Oruka Therapeutics. The dividend will be payable on August 28, 2024, to shareholders on record as of August 26, 2024. This special dividend is over 25% of ARCA's stock price on the declaration date, leading to specific trading regulations regarding due bills during the payment period. The merger is on track to close on August 29, 2024, pending the satisfaction of all necessary conditions.
Read more →ORKAARCA biopharma Announces 1-for-12 Reverse Stock Split in Connection with the Proposed Merger with Oruka Therapeutics Westminster, CO
ARCA biopharma has approved a 1-for-12 reverse stock split in anticipation of its merger with Oruka Therapeutics, expected to finalize on September 3, 2024. The action will reduce ARCA's outstanding shares significantly. Post-merger, the combined entity will trade under the new symbol 'ORKA'. Shareholders also approved an increase in authorized common stock from 100 million to 545 million shares, providing additional financial flexibility. However, potential risks and uncertainties surrounding the merger completion could impact investor sentiment.
Read more →ORKAARCA biopharma Declares Special Dividend in Connection with the Proposed Merger with Oruka Therapeutics Special dividend estimated to be $1.59 per share Payment of special dividend conditioned upon ARCA stockholder appro
ARCA biopharma has announced a special cash dividend of approximately $1.59 per share related to its proposed merger with Oruka Therapeutics. This dividend will only be paid if ARCA's stockholders approve the merger at a meeting on August 22, 2024. The merger aims to enhance ARCA’s capabilities in developing targeted therapies, while the final dividend amount may vary based on ARCA's net cash at the time of closing. If the merger is approved, it is expected to close on August 29, 2024.
Read more →ORKAARCA biopharma Announces Second Quarter 2024 Financial Results and Provides Corporate Update ------------------------------------------------------------------------------------------------------------ Westminster, CO
ARCA biopharma reported its financial results for the second quarter of 2024 and provided a corporate update, highlighting its continued exploration of strategic alternatives. The company is in a significant merger process with Oruka Therapeutics, which is intended to facilitate a tax-free reorganization. Despite holding cash sufficient to fund operations through 2025, ARCA faces uncertainties with the merger and ongoing losses impacting its financial stability. The expected increase in operational costs raises concerns about the company’s future viability.
Read more →ORKAOruka Therapeutics Announces Key Additions to Leadership Team and Board of Directors
Oruka Therapeutics has announced key additions to its leadership team, including Paul Quinlan as General Counsel and Alan Lada as VP of Investor Relations. Kristine Ball, President & CEO of Antiva Biosciences, has also been appointed to the Board of Directors. These appointments come as Oruka prepares to operate as a public company and advances its treatment programs for chronic skin diseases towards clinical trials.
Read more →ORKAOruka Therapeutics to Present at the 2024 Jefferies Global Healthcare Conference
Oruka Therapeutics, a biotechnology firm focused on novel biologics for chronic skin diseases, will present at the Jefferies Global Healthcare Conference on June 5, 2024. CEO Lawrence Klein, PhD, will showcase the company's efforts in addressing ailments such as plaque psoriasis. Oruka aims to achieve high disease clearance rates with treatments that require minimal dosing frequency. The presentation is expected to enhance the company's profile within the healthcare community.
Read more →ORKAOruka Therapeutics Expands Leadership Team with Appointment of Industry Veterans Drs. Joseph Senn and Rajiv Panwar
Oruka Therapeutics has announced the appointment of Drs. Joseph Senn and Rajiv Panwar to bolster its leadership team. Dr. Senn will serve as SVP of Nonclinical Research & Development, while Dr. Panwar takes on the role of VP and Head of Chemistry, Manufacturing, and Controls. Both appointments aim to enhance Oruka's portfolio of antibody therapies for chronic skin diseases, particularly promising candidates ORKA-001 and ORKA-002. The new leaders are expected to significantly contribute to the clinical advancement of these therapies.
Read more →ORKAARCA biopharma Announces First Quarter 2024 Financial Results and Provides Corporate Update ------------------------------------------------------------------------------------------------------------ • ARCA bioph
ARCA biopharma reported its first-quarter 2024 financial results and announced a merger agreement with Oruka Therapeutics. The company appointed Thomas Keuer as President and indicated that its cash reserves are projected to sustain operations until mid-2025. However, the future viability remains contingent on the success of the merger, with a current net loss reflecting increased operational costs. The rise in general and administrative expenses raises concerns about the company's financial stability amidst ongoing strategic reviews.
Read more →ORKAOruka Therapeutics Expands Leadership Team, Naming Joana Goncalves, MBChB, as Chief Medical Officer
Oruka Therapeutics has announced the expansion of its leadership team by appointing Dr. Joana Goncalves as Chief Medical Officer and Dr. Eugenia Levi as Vice President of Medical Affairs. Dr. Goncalves, with extensive experience in dermatology clinical development, aims to lead the company's global clinical and regulatory efforts. The company is focusing on advancing its innovative programs, ORKA-001 and ORKA-002, designed to treat chronic skin diseases with potentially superior efficacy and infrequent dosing. Both programs are expected to enter clinical trials in 2025, representing a significant development in treatment options for plaque psoriasis.
Read more →ORKAARCA biopharma and Oruka Therapeutics Announce Merger Agreement Merger to create a company focused on advancing Oruka s portfolio of novel biologics that aim to redefine the standard of care for patients with chronic ski
ARCA biopharma and Oruka Therapeutics have announced a merger agreement to create a new entity focused on developing novel biologics for chronic skin diseases. The combined company will retain the Oruka name and is set to advance clinical trials for its key programs, ORKA-001 and ORKA-002, expected to start in 2025. The merger is backed by a significant private investment of approximately $275 million, intended to fund operations through 2027. The deal has received approval from both companies’ boards and is targeted for completion in the third quarter of 2024, pending regulatory conditions.
Read more →ORKAARCA biopharma Announces 2023 Financial Results ------------------------------------------------------------------------------------------------------------ • Company is currently engaged in a strategic review pro
ARCA biopharma released its 2023 financial results, reporting a net loss of $5.3 million, an improvement over its $9.9 million loss in 2022. The company is undergoing a strategic review to evaluate development options and potential transactions to maximize stockholder value, but lacks a defined timeline for this process. Research and development expenses decreased significantly, reflecting a reduction in clinical activity. The company maintains enough cash reserves to support operations through mid-2025, despite uncertainties surrounding its future direction.
Read more →ORKAARCA biopharma Announces Third Quarter 2023 Financial Results ------------------------------------------------------------------------------------------------------------ • Company is currently engaged in a strate
ARCA biopharma reported its financial results for the third quarter of 2023, revealing a reduction in net loss compared to the same period last year. The company has initiated a strategic review process to explore potential asset development and collaboration opportunities, although there is no defined timeline for this process. Financially, ARCA holds $38.5 million in cash and equivalents, sufficient to support operations through the end of 2024, while general and administrative expenses showed consistency compared to previous periods.
Read more →ORKAARCA biopharma Announces Second Quarter 2023 Financial Results ------------------------------------------------------------------------------------------------------------ • Company is currently engaged in a strat
ARCA biopharma has announced its financial results for the second quarter of 2023, highlighting a net loss of $1.5 million. The company is engaged in a strategic review process to assess potential development options for its assets and partnerships. Although cash reserves are estimated to suffice through the end of 2024, the strategic review's indefinite timeline raises concerns about the company's future direction. Additionally, R&D expenses saw a notable decrease from the previous year following significant personnel reductions.
Read more →ORKAARCA biopharma Announces First Quarter 2023 Financial Results ------------------------------------------------------------------------------------------------------------ • Company is currently engaged in a strate
ARCA biopharma, Inc. reported its financial results for the first quarter of 2023, highlighting ongoing strategic evaluations aimed at enhancing stockholder value. The company has seen a reduction in R&D expenses, reflecting the completion of an earlier clinical trial. Despite a decline in net loss compared to the prior year, uncertainties remain with the strategic review process and increased G&A expenses from one-time costs. ARCA's current cash reserves are projected to support operations through mid-2024.
Read more →ORKAARCA biopharma Announces 2022 Financial Results and Provides Corporate Update ------------------------------------------------------------------------------------------------------------ • Company is currently eng
ARCA biopharma announced its financial results for 2022, reporting a net loss of $9.9 million and a significant reduction in research and development expenses. The company has retained a financial advisor to explore strategic options, including potential mergers or acquisitions. Current cash reserves are noted to be sufficient to support operations through mid-2024, but the ongoing strategic review process adds an element of uncertainty. The rise in general and administrative expenses highlights challenges in maintaining operational efficiency amidst a restructuring effort.
Read more →ORKAJaMES FLYNN joins arca biopharma board of directors Westminster, CO
JaMES FLYNN joins arca biopharma board of directors Westminster, CO, December 19, 2022 ARCA biopharma, Inc. (Nasdaq: ABIO) today announced that James Flynn has joined its Board of Directors. We are pleased to welcome James Flynn to our Board, said Robert E. Conway, Chairman of
Read more →ORKAARCA biopharma Announces Third Quarter 2022 Financial Results Company is currently engaged in a strategic review process, evaluating additional development of its assets, collaborations and other strategic options Westmi
ARCA biopharma Announces Third Quarter 2022 Financial Results Westminster, CO, October 28, 2022 - ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically targeted therapies for cardiovascular diseases, tod
Read more →ORKAARCA biopharma Announces Second Quarter 2022 Financial Results Company is currently engaged in a strategic review process, evaluating additional development of its assets, collaborations and other strategic options Westm
ARCA biopharma Announces Second Quarter 2022 Financial Results Westminster, CO, August 2, 2022 - ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically targeted therapies for cardiovascular diseases, toda
Read more →ORKAJacob ma-weaver joins arca biopharma board of DIRECTORS Westminster, CO
Jacob ma-weaver joins arca biopharma board of DIRECTORS Westminster, CO, June 21, 2022 - ARCA biopharma, Inc. (Nasdaq: ABIO) today announced that Jacob Ma-Weaver has joined its Board of Directors. "We are pleased to welcome Jacob Ma-Weaver, the managing member of ARCA's largest
Read more →ORKAARCA biopharma Retains Ladenburg Thalmann to Support Strategic Options Review Westminster, CO
ARCA biopharma Retains Ladenburg Thalmann to Support Strategic Options Review Westminster, CO, May 5, 2022 - ARCA biopharma, Inc. (Nasdaq: ABIO), today announced that it has retained Ladenburg Thalmann & Co. Inc. to act as its financial advisor. In April 2022, the Board of Dire
Read more →ORKAARCA biopharma Announces First Quarter 2022 Financial Results Company is currently engaged in a strategic review process, evaluating additional development of its assets, collaborations and other strategic options Westmi
ARCA biopharma Announces First Quarter 2022 Financial Results Westminster, CO, May 2, 2022 - ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically targeted therapies for cardiovascular diseases, today re
Read more →ORKAARCA biopharma Establishes Special Committee of the Board of Directors Westminster, CO
ARCA biopharma Establishes Special Committee of the Board of Directors Westminster, CO, April 18, 2022 - ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically targeted therapies for cardiovascular diseas
Read more →ORKAARCA biopharma Reports Topline Results for ASPEN-COVID-19 Phase 2b Clinical Trial For the entire cohort of COVID-19 hospitalized patients, the pooled lower and higher rNAPc2 dose groups demonstrated a reduction compared
ARCA biopharma Reports Topline Results for ASPEN-COVID-19 Phase 2b Clinical Trial Westminster, CO, March 31, 2022 - ARCA biopharma, Inc. (Nasdaq: ABIO), today announced results for ASPEN COVID 19, a 160 patient Phase 2b clinical trial evaluating rNAPc2, a highly potent and spec
Read more →ORKAARCA biopharma Announces 2021 Financial Results and Provides Corporate Update ------------------------------------------------------------------------------------------------------------ Topline data from Phase 2b ASPEN-
ARCA biopharma Announces 2021 Financial Results and Provides Corporate Update ------------------------------------------------------------------------------------------------------------ Westminster, CO, March 14, 2022 - ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical
Read more →ORKAARCA biopharma Announces Completion of Enrollment in Phase 2b ASPEN-COVID-19 Clinical Trial Evaluating rNAPc2 as a Potential Treatment for Patients Hospitalized with COVID-19 Topline readout of clinical trial results ant
ARCA biopharma Announces Completion of Enrollment in Phase 2b ASPEN-COVID-19 Clinical Trial Evaluating rNAPc2 as a Potential Treatment for Patients Hospitalized with COVID-19 Westminster, CO, December 2, 2021 - ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company app
Read more →ORKAARCA biopharma Announces Third Quarter 2021 Financial Results and Provides Corporate Update ------------------------------------------------------------------------------------------------------------ On-going Phase 2b c
ARCA biopharma Announces Third Quarter 2021 Financial Results and Provides Corporate Update ------------------------------------------------------------------------------------------------------------ Westminster, CO, November 2, 2021 - ARCA biopharma, Inc. (Nasdaq: ABIO), a bi
Read more →ORKAASPEN-COVID-19 Data and Safety Monitoring Committee Recommends Continuing Phase 2b Clinical Trial to Completion Based on Interim Analysis of Efficacy and Safety Data Enrollment completion anticipated by year end 2021 Top
ASPEN-COVID-19 Data and Safety Monitoring Committee Recommends Continuing Phase 2b Clinical Trial to Completion Based on Interim Analysis of Efficacy Westminster, CO, October 28, 2021 - ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company applying a precision medicin
Read more →ORKAARCA biopharma Announces Enrollment of First International Patient in Phase 2b Clinical Trial Evaluating rNAPc2 as a Potential Treatment for COVID-19 ----------------------------------------------------------------------
ARCA biopharma Announces Enrollment of First International Patient in Phase 2b Clinical Trial Evaluating rNAPc2 as a Potential Treatment for COVID-19 ------------------------------------------------------------------------------------------------------------ Westminster, CO, Se
Read more →ORKAARCA biopharma Announces Submission of PCT Patent Application for the Treatment of Coronavirus Infection and Associated Coagulopathy with rNAPc2 Westminster, CO
ARCA biopharma Announces Submission of PCT Patent Application for the Treatment of Coronavirus Infection and Associated Coagulopathy with rNAPc2 Westminster, CO, August 9, 2021 - ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company applying a precision medicine appro
Read more →ORKAARCA biopharma Announces Second Quarter 2021 Financial Results and Provides Corporate Update ------------------------------------------------------------------------------------------------------------ Phase 2b clinical
ARCA biopharma Announces Second Quarter 2021 Financial Results and Provides Corporate Update ------------------------------------------------------------------------------------------------------------ Westminster, CO, August 4, 2021 - ARCA biopharma, Inc. (Nasdaq: ABIO), a bio
Read more →ORKAGencaro Atrial Fibrillation Phase 2B Results Selected for Publication in Circulation: Arrhythmia and Electrophysiology Analysis in full patient cohort shows Gencaro effect compared to standard of care In the GENETIC-AF e
Gencaro Atrial Fibrillation Phase 2B Results Selected for Publication in Circulation: Arrhythmia and Electrophysiology Westminster, CO, July 28, 2021 - ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetica
Read more →ORKAARCA biopharma Provides Update on ASPEN-COVID-19 Phase 2b Clinical Trial Evaluating rNAPc2 as a Potential Treatment for COVID-19 -------------------------------------------------------------------------------------------
ARCA biopharma Provides Update on ASPEN-COVID-19 Phase 2b Clinical Trial Evaluating rNAPc2 as a Potential Treatment for COVID-19 ------------------------------------------------------------------------------------------------------------ Westminster, CO, July 13, 2021 - ARCA bi
Read more →ORKAARCA biopharma Announces rNAPc2 COVID-19 Patent Assignment Agreement ------------------------------------------------------------------------------------------------------------ Provides exclusive world-wide patent right
ARCA biopharma Announces rNAPc2 COVID-19 Patent Assignment Agreement ------------------------------------------------------------------------------------------------------------ Westminster, CO, July 7, 2021 - ARCA biopharma, Inc. (Nasdaq: ABIO) today announced it has entered i
Read more →ORKAARCA biopharma Announces First Quarter 2021 Financial Results and Provides Corporate Update ------------------------------------------------------------------------------------------------------------ Topline data from P
ARCA biopharma Announces First Quarter 2021 Financial Results and Provides Corporate Update ------------------------------------------------------------------------------------------------------------ Westminster, CO, May 11, 2021 - ARCA biopharma, Inc. (Nasdaq: ABIO), a biopha
Read more →ORKAARCA biopharma Announces C. Jeff Dekker to be Appointed Chief Financial Officer Westminster, CO
ARCA biopharma Announces C. Jeff Dekker to be Appointed Chief Financial Officer Westminster, CO, May 3, 2021 - ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically targeted therapies for cardiovascular
Read more →ORKAARCA biopharma Announces 2020 Financial Results and Provides Corporate Update ------------------------------------------------------------------------------------------------------------ Topline data from Phase 2b clinic
ARCA biopharma Announces 2020 Financial Results and Provides Corporate Update ------------------------------------------------------------------------------------------------------------ Westminster, CO, March 18, 2021 - ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical
Read more →ORKAARCA biopharma Announces First Patients Enrolled in ASPEN-COVID-19 Phase 2b Clinical Trial Evaluating rNAPc2 (AB201) as a Potential Treatment for COVID 19 - rNAPc2 development focused on unmet need for treatments in hosp
ARCA biopharma Announces First Patients Enrolled in ASPEN-COVID-19 Phase 2b Clinical Trial Evaluating rNAPc2 (AB201) as a Potential Treatment for COVID 19 Westminster, CO, December 15, 2020 - ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company applying a precision m
Read more →ORKAAB201 Development as a Potential Treatment for COVID 19 Receives U.S. FDA Fast Track Designation - Development addresses need for treatments for patients hospitalized with COVID-19 whether vaccines are available or not -
AB201 Development as a Potential Treatment for COVID 19 Receives U.S. FDA Fast Track Designation Westminster, CO, November 23, 2020 - ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically targeted therap
Read more →ORKAARCA biopharma Announces Third Quarter 2020 Financial Results and Provides Corporate Update ------------------------------------------------------------------------------------------------------------ • Initiation
ARCA biopharma Announces Third Quarter 2020 Financial Results and Provides Corporate Update ------------------------------------------------------------------------------------------------------------ Westminster, CO, November 2, 2020 - ARCA biopharma, Inc. (Nasdaq: ABIO), a b
Read more →ORKAARCA biopharma Announces FDA Approval of IND Application for AB201 as a Potential Treatment for COVID 19 - Initiation of Phase 2b clinical trial anticipated in Q4 2020 - Trial to enroll approximately 100 patients hospita
ARCA biopharma Announces FDA Approval of IND Application for AB201 as a Potential Treatment for COVID 19 Westminster, CO, October 7, 2020 - ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically targeted
Read more →ORKAARCA biopharma Announces Submission of IND Application to U.S. FDA for AB201 as a Potential Treatment for covid-19 Westminster, CO
ARCA biopharma Announces Submission of IND Application to U.S. FDA for AB201 as a Potential Treatment for covid-19 Westminster, CO, September 21, 2020 - ARCA biopharma, Inc. (Nasdaq: ABIO) a biopharmaceutical company applying a precision medicine approach to developing genetical
Read more →ORKAARCA Biopharma announces Completion of FDA Pre-ind consultation under coronavirus treatment acceleration program for ab201 as a potential treatment for severe covid-19 ----------------------------------------------------
ARCA Biopharma announces Completion of FDA Pre-ind consultation under coronavirus treatment acceleration program for ab201 as a potential treatment for severe covid-19 ------------------------------------------------------------------------------------------------------------ W
Read more →ORKAARCA Biopharma announces second quarter 2020 financial results AND Provides CorporatE update ------------------------------------------------------------------------------------------------------------ • AB201 bei
ARCA Biopharma announces second quarter 2020 financial results AND Provides CorporatE update ------------------------------------------------------------------------------------------------------------ Westminster, CO, August 5, 2020 - ARCA biopharma, Inc. (Nasdaq: ABIO), a bi
Read more →ORKAARCA Biopharma announces CLOSING OF $6.1 million registered direct offering Westminster, CO
ARCA Biopharma announces CLOSING OF $6.1 million registered Westminster, CO, June 3, 2020 - ARCA biopharma, Inc. (Nasdaq: ABIO) a late stage biopharmaceutical company applying a precision medicine approach to developing genetically targeted therapies for cardiovascular diseases,
Read more →ORKAARCA Biopharma announces $9.4 million registered direct offering Westminster, CO
ARCA Biopharma announces $9.4 million registered Westminster, CO, June 1, 2020 - ARCA biopharma, Inc. (Nasdaq: ABIO) a late stage biopharmaceutical company applying a precision medicine approach to developing genetically targeted therapies for cardiovascular diseases, today anno
Read more →ORKAARCA Biopharma announces AB201 development program for treatment of covid-19 ASSOCIATED COAGulopAthy ------------------------------------------------------------------------------------------------------------ • A
ARCA Biopharma announces AB201 development program for treatment of covid-19 ASSOCIATED COAGulopAthy ------------------------------------------------------------------------------------------------------------ Westminster, CO, May 28, 2020 - ARCA biopharma, Inc. (Nasdaq: ABIO)
Read more →ORKAARCA Biopharma announces First quarter 2020 financial results AND Provides CorporatE update ------------------------------------------------------------------------------------------------------------ • U.S. FDA S
ARCA Biopharma announces First quarter 2020 financial results AND Provides CorporatE update ------------------------------------------------------------------------------------------------------------ Westminster, CO, May 6, 2020 - ARCA biopharma, Inc. (Nasdaq: ABIO), a biopha
Read more →ORKAARCA Biopharma announces FISCAL YEAR 2019 financial results AND Provides CorporatE update ------------------------------------------------------------------------------------------------------------ • U.S. FDA Spe
ARCA Biopharma announces FISCAL YEAR 2019 financial results AND Provides CorporatE update ------------------------------------------------------------------------------------------------------------ Westminster, CO, February 18, 2020 - ARCA biopharma, Inc. (Nasdaq: ABIO), a bio
Read more →ORKAARCA Biopharma announces third quarter 2019 financial results AND Provides CorporatE update ------------------------------------------------------------------------------------------------------------ • PRECISION-
ARCA Biopharma announces third quarter 2019 financial results AND Provides CorporatE update ------------------------------------------------------------------------------------------------------------ Westminster, CO, November 6, 2019 - ARCA biopharma, Inc. (Nasdaq: ABIO), a bi
Read more →ORKAARCA Biopharma announces second quarter 2019 financial results AND Provides CorporatE update - FDA SPA Agreement for Phase 3 atrial fibrillation trial (PRECISION-AF) amended to expand patient population to include heart
ARCA Biopharma announces second quarter 2019 financial results AND Provides CorporatE update Westminster, CO, August 1, 2019 - ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically-targeted therapies for
Read more →ORKAARCA Biopharma announces first quarter 2019 financial results AND Provides CorporatE update Westminster, CO
ARCA Biopharma announces first quarter 2019 financial results AND Provides CorporatE update Westminster, CO, May 8, 2019 - ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically-targeted therapies for car
Read more →ORKASafe Harbor Statement This presentation contains "forward-looking statements" for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. These statements include, but are not limite
ARCA biopharma Pharmacogenetic Precision Medicine for Cardiovascular Diseases April 2019 Nasdaq: ABIO Exhibit 99.1 Safe Harbor Statement This presentation contains "forward-looking statements" for purposes of the safe harbor provided by the Private Securities Litigation Reform A
Read more →ORKAARCA Biopharma announces FISCAL YEAR 2018 financial results AND Provides Corporate update -------------------------------------------------------------------------------------------------- Initiation of Pivotal Phase 3 P
ARCA Biopharma announces FISCAL YEAR 2018 financial results AND Provides Corporate update -------------------------------------------------------------------------------------------------- Initiation of Pivotal Phase 3 PRECISION-AF Clinical Trial Anticipated in Fourth Quarter
Read more →ORKAARCA Biopharma announces FDA agreement for a single Phase 3 clinical trial to support approval for the first genetically-targeted cardiovascular DrUG - FDA Special Protocol Assessment agreement granted for PRECISION-AF c
ARCA Biopharma announces FDA agreement for a single Phase 3 clinical trial to support approval for the first genetically-targeted cardiovascular DrUG Westminster, CO, February 20, 2019 - ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company applying a precision medic
Read more →ORKAARCA Biopharma updates Special protocol assessment Request to FDA for gencaro phase 3 atrial fibrillation clinical trial - Phase 3 atrial fibrillation trial planned in population with no effective or FDA approved therapi
ARCA Biopharma updates Special protocol assessment Request to FDA for gencaro phase 3 atrial fibrillation clinical trial Westminster, CO, December 20, 2018 - ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company applying a precision medicine approach to developing gen
Read more →ORKAARCA Biopharma announces THIRd quarter 2018 financial results AND Provides Corporate update Westminster, CO
ARCA Biopharma announces THIRd quarter 2018 financial results AND Provides Corporate update Westminster, CO, November 14, 2018 - ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically-targeted therapies f
Read more →ORKAARCA Biopharma Submits Special protocol assessment Request to FDA for gencaro phase 3 atrial fibrillation clinical trial - Gencaro potentially the first genetically-targeted treatment for heart failure patients at risk f
ARCA Biopharma Submits Special protocol assessment Request to FDA for gencaro phase 3 atrial fibrillation clinical trial Westminster, CO, September 18, 2018 - ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company applying a precision medicine approach to developing ge
Read more →ORKAARCA Biopharma announces second quarter 2018 financial results AND Provides Corporate update -------------------------------------------------------------------------------------------------- End-of-Phase 2 Meeting with
ARCA Biopharma announces second quarter 2018 financial results AND Provides Corporate update -------------------------------------------------------------------------------------------------- End-of-Phase 2 Meeting with the U.S. FDA on Gencaro Atrial Fibrillation Development Pl
Read more →ORKAARCA biopharma announces positive outcome of end-of-phase 2 meeting with fda on gencaro development for atrial fibrillatioN - Single Phase 3 trial may be sufficient for approval of atrial fibrillation indication - Phase
ARCA biopharma announces positive outcome of end-of-phase 2 meeting with fda on gencaro development for atrial fibrillatioN Westminster, CO, July 31, 2018 - ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company applying a precision medicine approach to developing gene
Read more →ORKAGENETIC-AF phase 2b clinical trial results presented in late breaking presentation at european society of cardiology heart failure 2018 world congress ---------------------------------------------------------------------
GENETIC-AF phase 2b clinical trial results presented in late breaking presentation at european society of cardiology heart failure 2018 world congress ------------------------------------------------------------------------------------------------------ End-of-Phase 2 Meeting
Read more →ORKAARCA Biopharma announces first quarter 2018 financial results AND Provides Corporate update -------------------------------------------------------------------------------------------------- End-of-Phase 2 Meeting with t
ARCA Biopharma announces first quarter 2018 financial results AND Provides Corporate update -------------------------------------------------------------------------------------------------- End-of-Phase 2 Meeting with the U.S. FDA Scheduled for the Last Week of June to Review
Read more →ORKAARCA biopharma and MeDtronic extend Gencaro clinical trial collaboration agreemeNt Westminster, CO
ARCA biopharma and MeDtronic extend Gencaro clinical trial collaboration agreemeNt Westminster, CO, April 23, 2018 - ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically-targeted therapies for cardiovas
Read more →ORKAARCA Biopharma announces fiscal year 2017 financial results AND Provides Corporate update -------------------------------------------------------------------------------------------------- ARCA is Requesting a Meeting wi
ARCA Biopharma announces fiscal year 2017 financial results AND Provides Corporate update -------------------------------------------------------------------------------------------------- ARCA is Requesting a Meeting with the U.S. FDA for the Second Quarter of 2018 to Review
Read more →ORKAARCA Biopharma reports topline Phase 2b results for genetic-af clinical trial -------------------------------------------------------------------------------------------------- Gencaro Demonstrates Comparable Efficacy to
ARCA Biopharma reports topline Phase 2b results for genetic-af clinical trial -------------------------------------------------------------------------------------------------- Gencaro Demonstrates Comparable Efficacy to Active Control and Trend for Potential Gencaro Superior
Read more →ORKAARCA Biopharma announces completion of genetic-af Phase 2b clinical trial -------------------------------------------------------------------------------------------------- GENETIC-AF Evaluating Gencaro as Potentially Fi
ARCA Biopharma announces completion of genetic-af Phase 2b clinical trial -------------------------------------------------------------------------------------------------- GENETIC-AF Evaluating Gencaro as Potentially First Genetically-Targeted Treatment for Atrial Fibrillatio
Read more →ORKAARCA Biopharma ANNOUNCES issuance of european patent FOR TREATING cardiovascular diseases and conditions with a new Chemical entity utilizing genetic targetinG ------------------------------------------------------------
ARCA Biopharma ANNOUNCES issuance of european patent FOR TREATING cardiovascular diseases and conditions with a new Chemical entity utilizing genetic targetinG -------------------------------------------------------------------------------------------------- ARCA Plans Genetica
Read more →ORKAARCA Biopharma announces THIRD quarter 2017 financial results and provides business update -------------------------------------------------------------------------------------------------- GENETIC-AF Phase 2B Clinical T
ARCA Biopharma announces THIRD quarter 2017 financial results and provides business update -------------------------------------------------------------------------------------------------- GENETIC-AF Phase 2B Clinical Trial Data Anticipated in First Quarter of 2018 Westminst
Read more →ORKAARCA Biopharma announces completion of enrollment for genetic-af Phase 2b clinical trial -------------------------------------------------------------------------------------------------- GENETIC-AF Evaluating Gencaro as
ARCA Biopharma announces completion of enrollment for genetic-af Phase 2b clinical trial -------------------------------------------------------------------------------------------------- GENETIC-AF Evaluating Gencaro as Potentially First Genetically-Targeted Treatment for At
Read more →ORKAARCA Biopharma announces GENETIC-AF Data and Safety Monitoring Board recommendation to complete phase 2b GENETIC-AF clinical trial based on efficacy and safety data in Phase 2b interim analysis --------------------------
ARCA Biopharma announces GENETIC-AF Data and Safety Monitoring Board recommendation to complete phase 2b GENETIC-AF clinical trial based on efficacy and safety data in Phase 2b interim analysis -------------------------------------------------------------------------------------
Read more →ORKAARCA Biopharma announces SECOND quarter 2017 financial results and provides business update -------------------------------------------------------------------------------------------------- Outcome of GENETIC-AF Data an
ARCA Biopharma announces SECOND quarter 2017 financial results and provides business update -------------------------------------------------------------------------------------------------- Outcome of GENETIC-AF Data and Safety Monitoring Board Phase 2B Interim Efficacy Analy
Read more →ORKAARCA Biopharma announces database lock for genetic-af Phase 2b interim efficacy analysis - DSMB Recommendation anticIpated in August 2017 ----------------------------------------------------------------------------------
ARCA Biopharma announces database lock for genetic-af Phase 2b interim efficacy analysis - DSMB Recommendation anticIpated in August 2017 -------------------------------------------------------------------------------------------------- GENETIC-AF Evaluating Gencaro as Potenti
Read more →ORKAARCA Biopharma announces first quarter 2017 financial results and provides business update -------------------------------------------------------------------------------------------------- Outcome of GENETIC-AF Phase 2B
ARCA Biopharma announces first quarter 2017 financial results and provides business update -------------------------------------------------------------------------------------------------- Outcome of GENETIC-AF Phase 2B Interim Efficacy Analysis Anticipated in September 2017
Read more →ORKAARCA Biopharma announces 200 th patient randomized into the GENETIC-AF SEAMLESS design Phase 2B/3 clinical trial -------------------------------------------------------------------------------------------------- Outcome
ARCA Biopharma announces 200th patient randomized into the GENETIC-AF SEAMLESS design Phase 2B/3 clinical trial -------------------------------------------------------------------------------------------------- Outcome of Phase 2B Interim Efficacy Analysis Anticipated in Septe
Read more →ORKAARCA Biopharma announces fiscal year 2016 financial results and provides business update -------------------------------------------------------------------------------------------------- GENETIC-AF Phase 2B/3 Clinical T
ARCA Biopharma announces fiscal year 2016 financial results and provides business update -------------------------------------------------------------------------------------------------- GENETIC-AF Phase 2B/3 Clinical Trial Evaluating Gencaro as Potentially First Genetically-T
Read more →ORKAARCA Biopharma announces 175 th patient randomized into the GENETIC-AF Phase 2B/3 clinical trial -------------------------------------------------------------------------------------------------- Outcome of DSMB Interim
ARCA Biopharma announces 175th patient randomized into the GENETIC-AF Phase 2B/3 clinical trial -------------------------------------------------------------------------------------------------- Outcome of DSMB Interim Efficacy Analysis Anticipated in the Third Quarter of 2017
Read more →ORKAAnders Hove, MD joins arca biopharma board of directors Westminster, CO
Anders Hove, MD joins arca biopharma board of directors Westminster, CO, February 21, 2017 - ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically-targeted therapies for cardiovascular diseases, today an
Read more →ORKAARCA Biopharma announces 150 th patient randomized into the GENETIC-AF Phase 2B/3 clinical trial -------------------------------------------------------------------------------------------------- Outcome of DSMB Interim
ARCA Biopharma announces 150th patient randomized into the GENETIC-AF Phase 2B/3 clinical trial -------------------------------------------------------------------------------------------------- Outcome of DSMB Interim Efficacy Analysis Anticipated in the Third Quarter of 2017
Read more →ORKAARCA Biopharma announces THIRd quarter 2016 financial results and provides business update ------------------------------------------------------------------------------- 125 th Patient Randomized into the GENETIC-AF Pha
ARCA Biopharma announces THIRd quarter 2016 financial results and provides business update ------------------------------------------------------------------------------- 125th Patient Randomized into the GENETIC-AF Phase 2B/3 Clinical Trial Evaluating Gencaro as Potentially F
Read more →ORKAARCA biopharma announces randomization of first european patients in GENETIC-AF phase 2b/3 clinical trial ------------------------------------------------------------------------------- Approximately Six Million Patients
ARCA biopharma announces randomization of first european patients in GENETIC-AF phase 2b/3 clinical trial ------------------------------------------------------------------------------- Approximately Six Million Patients in Europe Estimated to Have Atrial Fibrillation --------
Read more →ORKAARCA Biopharma announces 100 th patient randomized into the GENETIC-AF Phase 2B/3 clinical trial -------------------------------------------------------------------------------------------------- GENETIC-AF Evaluating Ge
ARCA Biopharma announces 100th patient randomized into the GENETIC-AF Phase 2B/3 clinical trial -------------------------------------------------------------------------------------------------- GENETIC-AF Evaluating Gencaro as Potentially First Genetically-Targeted Treatment
Read more →ORKAARCA Biopharma announces second quarter 2016 financial results and provides business update ------------------------------------------------------------------------------- Outcome of GENETIC-AF Clinical Trial Interim Eff
ARCA Biopharma announces second quarter 2016 financial results and provides business update ------------------------------------------------------------------------------- Outcome of GENETIC-AF Clinical Trial Interim Efficacy Analysis Anticipated in the Second Quarter of 2017
Read more →ORKAARCA Biopharma announces first quarter 2016 financial results and provides business updatE Westminster, CO
ARCA Biopharma announces first quarter 2016 financial results and provides business updatE Westminster, CO, May 11, 2016 - ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company developing genetically-targeted therapies for cardiovascular diseases, today reported fina
Read more →ORKAARCA Biopharma announces 75 th patient enrolled in GENETIC-AF Phase 2B/3 clinical trial -------------------------------------------------------------------------------------------------- GENETIC-AF Evaluating Gencaro as
ARCA Biopharma announces 75th patient enrolled in GENETIC-AF Phase 2B/3 clinical trial -------------------------------------------------------------------------------------------------- GENETIC-AF Evaluating Gencaro as Potentially First Genetically-Targeted Treatment for Atria
Read more →ORKAARCA Biopharma announces fiscal year 2015 financial results and provides business update -------------------------------------------------------------------------------------------------- GENETIC-AF Trial Evaluating Genc
ARCA Biopharma announces fiscal year 2015 financial results and provides business update -------------------------------------------------------------------------------------------------- GENETIC-AF Trial Evaluating Gencaro as a Potential Treatment for Atrial Fibrillation ----
Read more →ORKAgenetic-AF clinical trial for prevention of atrial fibrillation enrolls 50 th patient -------------------------------------------------------------------------------------------------- Enrollment for Phase 2B Interim Ana
genetic-AF clinical trial for prevention of atrial fibrillation enrolls 50th patient -------------------------------------------------------------------------------------------------- Enrollment for Phase 2B Interim Analysis of Efficacy Data Expected by Year-End 2016 Westmins
Read more →ORKAARCA Biopharma announces third quarter 2015 financial results and provides business update -------------------------------------------------------------------------------------------------- GENETIC-AF Trial Evaluating Ge
ARCA Biopharma announces third quarter 2015 financial results and provides business update -------------------------------------------------------------------------------------------------- GENETIC-AF Trial Evaluating Gencaro as a Potential Treatment for Atrial Fibrillation --
Read more →ORKAgencaro TM potential efficacy preventing atrial flutter in Heart failure paper to be presented at 2015 HFSA aNNUAL SCIENTIFIC meeting --------------------------------------------------------------------------------------
gencaroTM potential efficacy preventing atrial flutter in Heart failure paper to be presented at 2015 HFSA aNNUAL SCIENTIFIC meeting -------------------------------------------------------------------------------------------------- The Paper, Which Describes Pharmacogenetic Enh
Read more →ORKAARCA Biopharma announces Second quarter 2015 operating results and provides Update on recent accomplishments -------------------------------------------------------------------------------------------------- GENETIC-AF T
ARCA Biopharma announces Second quarter 2015 operating results and provides Update on recent accomplishments -------------------------------------------------------------------------------------------------- GENETIC-AF Trial Evaluating Gencaro as a Potential Treatment for Atria
Read more →ORKAARCA Biopharma Announces $37 Million private placement -------------------------------------------------------------------------------------------------- Proceeds to Support Advancement of Bucindolol Phase 2B/3 Clinical
ARCA Biopharma Announces $37 Million private placement -------------------------------------------------------------------------------------------------- Proceeds to Support Advancement of Bucindolol Phase 2B/3 Clinical Development ---------------------------------------------
Read more →ORKAARCA Biopharma receives FDA FAST TRACK DESIGNATION FOR gencaro TM atrial fibrillation DEVELOPMENT in a genetically targeted heart failure population Westminster, CO
ARCA Biopharma receives FDA FAST TRACK DESIGNATION FOR gencaroTM atrial fibrillation DEVELOPMENT in a genetically targeted heart failure population Westminster, CO, April 13, 2015 - ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company developing genetically-targete
Read more →ORKAARCA Biopharma provides genetic-af clinical trial update GENETIC-AF Trial Evaluating Gencaro as Potential Treatment for Atrial Fibrillation Protocol Amended to Broaden Trial Population and Increase Enrollment Rate Phase
ARCA Biopharma provides genetic-af clinical trial update GENETIC-AF Trial Evaluating Gencaro as Potential Treatment for Atrial Fibrillation Protocol Amended to Broaden Trial Population and Increase Enrollment Rate Phase 2B of GENETIC-AF Anticipated to Complete Enrollment by Ye
Read more →ORKAARCA BIOPHARMA ANNOUNCES PATENT ISSUANCE FOR METHODS AND COMPOSITIONS OF S-ISOMER FORMULATION OF GENCARO Patent Includes Methods for Treating Multiple Cardiovascular Disease Indications Westminster, CO
ARCA BIOPHARMA ANNOUNCES PATENT ISSUANCE FOR METHODS AND COMPOSITIONS OF S-ISOMER FORMULATION OF GENCARO Includes Methods for Treating Multiple Cardiovascular Disease Indications Westminster, CO, February 4, 2015 ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical compan
Read more →ORKAARCA BIOPHARMA ANNOUNCES ACTIVATION OF FIRST CANADIAN GENETIC-AF CLINICAL TRIAL SITE Clinical Trial is Evaluating Gencaro as a Potential Treatment for Atrial Fibrillation Approximately 60 Trial Sites Planned in the Unite
ARCA BIOPHARMA ANNOUNCES ACTIVATION OF FIRST CANADIAN GENETIC-AF CLINICAL TRIAL SITE is Evaluating Gencaro as a Potential Treatment for Atrial Fibrillation 60 Trial Sites Planned in the United States and Canada Westminster, CO, December 11, 2014 ARCA biopharma, Inc. (Nasdaq:
Read more →ORKAARCA BIOPHARMA RECEIVES FDA ORPHAN DRUG DESIGNATION FOR RNAPC2 AS A POTENTIAL TREATMENT FOR EBOLA rNAPc2 Previously Demonstrated Post-Exposure Efficacy in NHP Models of Ebola HFV rNAPc2 Previously Tested in Over 700 Huma
ARCA BIOPHARMA RECEIVES FDA ORPHAN DRUG DESIGNATION FOR RNAPC2 AS A POTENTIAL TREATMENT FOR EBOLA rNAPc2 Previously Demonstrated Post-Exposure Efficacy in NHP Models of Ebola HFV rNAPc2 Previously Tested in Over 700 Human Patients in Nine Phase 1 and 2 Cardiovascular Disease C
Read more →ORKAARCA BIOPHARMA ANNOUNCES MANAGEMENT TRANSITIONS Westminster, CO
ARCA BIOPHARMA ANNOUNCES MANAGEMENT TRANSITIONS Westminster, CO, December 1, 2014 ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company developing genetically-targeted therapies for cardiovascular diseases, today announced three management team transitions. Patrick
Read more →ORKAARCA BIOPHARMA ANNOUNCES HEALTH CANADA ACCEPTANCE OF GENETIC-AF CLINICAL TRIAL APPLICATION Canadian Site Activation for Phase 2B/3 Clinical Trial to Begin in 2014 Gencaro Potentially the First Genetically-Targeted Cardio
ARCA BIOPHARMA ANNOUNCES HEALTH CANADA ACCEPTANCE OF GENETIC-AF CLINICAL TRIAL APPLICATION Canadian Site Activation for Phase 2B/3 Clinical Trial to Begin in 2014 Gencaro Potentially the First Genetically-Targeted Cardiovascular Treatment Westminster, CO, August 18, 2014 ARCA
Read more →ORKAROBERT E. CONWAY ELECTED CHAIRMAN OF ARCA BIOPHARMA BOARD OF DIRECTORS Westminster, CO
ROBERT E. CONWAY ELECTED CHAIRMAN OF ARCA BIOPHARMA June 9, 2014 ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company developing genetically-targeted therapies for cardiovascular diseases, today announced that Robert E. Conway, has been elected Chairman of the Compa
Read more →ORKADAN MITCHELL JOINS ARCA BIOPHARMA BOARD OF DIRECTORS Westminster, CO, February 12 2014 ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company developing genetically-targeted therapies for cardiovascular disease
DAN MITCHELL JOINS ARCA BIOPHARMA BOARD OF DIRECTORS Westminster, CO, February 12 2014 ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company developing genetically-targeted therapies for cardiovascular diseases, today announced that Dan Mitchell has been appointed to
Read more →ORKAARCA BIOPHARMA ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK AND WARRANTS Westminster, CO
ARCA BIOPHARMA ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK AND WARRANTS Westminster, CO, February 3, 2014 ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company developing genetically-targeted therapies for cardiovascular diseases, today announced that it inten
Read more →ORKAARCA BIOPHARMA TO PRESENT AT BIOTECH SHOWCASE 2014 Westminster, CO
ARCA BIOPHARMA TO PRESENT AT BIOTECH SHOWCASE 2014 Westminster, CO, January 7, 2014 ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company developing genetically-targeted therapies for cardiovascular diseases, today announced that Dr. Michael R. Bristow, president and
Read more →ORKAARCA BIOPHARMA ANNOUNCES US FDA ACCEPTANCE OF GENCARO IND APPLICATION FOR THE TREATMENT OF ATRIAL FIBRILLATION Phase 2B/3 GENETIC-AF Trial on Track to Begin Patient Enrollment in Q1 2014 Gencaro Potentially the First Gen
ARCA BIOPHARMA ANNOUNCES US FDA ACCEPTANCE OF GENCARO IND APPLICATION FOR THE TREATMENT OF ATRIAL FIBRILLATION Phase 2B/3 GENETIC-AF Trial on Track to Begin Patient Enrollment in Q1 2014 Gencaro Potentially the First Genetically-Targeted Cardiovascular Treatment Westminster,
Read more →ORKAARCA BIOPHARMA ANNOUNCES RESIGNATION FROM BOARD OF DIRECTORS Westminster, CO
ARCA BIOPHARMA ANNOUNCES RESIGNATION FROM BOARD OF DIRECTORS Westminster, CO, November 21, 2013 ARCA biopharma, Inc. (Nasdaq: ABIO), today announced that John L. Zabriskie, PhD, has resigned from the Company s Board of Directors. Dr. Zabriskie resigned effective November 19, 2
Read more →ORKAARCA BIOPHARMA ANNOUNCES CLINICAL TRIAL AGREEMENT FOR GENETIC-AF TRIAL Gencaro Potentially the First Genetically-Targeted AF Prevention Treatment Westminster, CO
ARCA BIOPHARMA ANNOUNCES CLINICAL TRIAL AGREEMENT FOR Gencaro Potentially the First Genetically-Targeted AF Prevention Treatment Westminster, CO, November 6, 2013 ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company developing genetically-targeted therapies for car
Read more →ORKAARCA BIOPHARMA ANNOUNCES IND SUBMISSION TO US FDA FOR GENCARO FOR THE TREATMENT OF ATRIAL FIBRILLATION GENETIC-AF Trial Data Safety Monitoring Board Established Westminster, CO
ARCA BIOPHARMA ANNOUNCES IND SUBMISSION TO US FDA FOR GENCARO FOR THE TREATMENT OF ATRIAL FIBRILLATION GENETIC-AF Trial Data Safety Monitoring Board Established Westminster, CO, October 29, 2013 ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company developing gene
Read more →ORKAROBERT E. CONWAY APPOINTED TO ARCA BIOPHARMA BOARD OF DIRECTORS Broomfield, CO
ROBERT E. CONWAY APPOINTED TO ARCA BIOPHARMA BOARD OF DIRECTORS Broomfield, CO, September 4, 2013 ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company developing genetically-targeted therapies for cardiovascular diseases, today announced that Robert E. Conway, has b
Read more →ORKARAYMOND L. WOOSLEY, M.D., PH.D. APPOINTED TO ARCA BIOPHARMA BOARD OF DIRECTORS Broomfield, CO
RAYMOND L. WOOSLEY, M.D., PH.D. APPOINTED TO ARCA BIOPHARMA BOARD OF DIRECTORS Broomfield, CO, July 30, 2013 ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company developing genetically-targeted therapies for cardiovascular diseases, today announced that Raymond L. W
Read more →ORKAARCA biopharma Announces Additions to GENETIC-AF Leadership Team Team Will Oversee Execution of GENETIC-AF Clinical Trial Evaluating Gencaro as Potential Treatment for Atrial Fibrillation Broomfield, Colorado
ARCA biopharma Announces Additions to GENETIC-AF Leadership Team Team Will Oversee Execution of GENETIC-AF Clinical Trial Evaluating Gencaro as Potential Treatment for Atrial Fibrillation Broomfield, Colorado, July 22, 2013 ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutic
Read more →ORKAARCA BIOPHARMA PROVIDES BUSINESS UPDATE GENETIC-AF Trial Evaluating Gencaro as Potential Treatment for Atrial Fibrillation Planned to Begin Patient Enrollment in Q1 2014 ARCA and Medtronic, Inc. are Collaborating on Phas
ARCA BIOPHARMA PROVIDES BUSINESS UPDATE GENETIC-AF Trial Evaluating Gencaro as Potential Treatment for Atrial Fibrillation Planned to Begin Patient Enrollment in Q1 ARCA and Medtronic, Inc. are Collaborating on Phase 2B Portion of GENETIC-AF Broomfield, CO, July 17, 2013 ARCA
Read more →ORKAChristopher D. Ozeroff Senior Vice President and General Counsel 720.940.2100 GENCARO TM POTENTIAL EFFICACY IN PREVENTING ATRIAL FIBRILLATION PAPER PUBLISHED IN JACC: HEART FAILURE Pharmacogenetic Enhancement of
Christopher D. Ozeroff Senior Vice President and General Counsel GENCAROTM POTENTIAL EFFICACY IN PREVENTING ATRIAL FIBRILLATION PAPER PUBLISHED IN JACC: HEART FAILURE Pharmacogenetic Enhancement of Effectiveness for Prevention of Atrial Fibrillation in Patients with Heart Fai
Read more →ORKAARCA BIOPHARMA ANNOUNCES PRICING OF $20 MILLION EQUITY OFFERING Broomfield, CO
ARCA BIOPHARMA ANNOUNCES PRICING OF $20 MILLION EQUITY OFFERING Broomfield, CO, May 30, 2013 ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company developing genetically-targeted therapies for cardiovascular diseases, today announced the pricing of the previously ann
Read more →ORKADerek Cole Investor Relations Advisory Solutions 720.940.2163 derek.cole@arcabiopharma.com ARCA ANNOUNCES DEATH OF BOARD MEMBER BURTON E. SOBEL, PREEMINENT PHYSICIAN SCIENTIST AND ACADEMIC LEADER Broomfield, CO
Investor Relations Advisory Solutions derek.cole@arcabiopharma.com ARCA ANNOUNCES DEATH OF BOARD MEMBER BURTON E. SOBEL, PREEMINENT PHYSICIAN SCIENTIST AND ACADEMIC LEADER Broomfield, CO, May 6, 2013 ARCA biopharma, Inc. (Nasdaq: ABIO), today announced that Burton E. Sobel, 7
Read more →ORKASafe Harbor Statement 2 This presentation contains forward looking statements for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. These statements include, but are not limite
Metoprolol CR/XL, Prevention of Recurrent Atrial Fibrillation in Persistent AF HFREF Patients with the 1 389 Arg/Arg Genotype post Electrical Cardioversion (ECV), + Adaptive Design to Phase 3 Projected timeline: Trial Initiation Q4 2013 Ph 2b Trial Data Q4 2015 Ph 3 Trial data Q4
Read more →ORKADerek Cole Vice President of Investor Relations 720.940.2100 ARCA BIOPHARMA AND MEDTRONIC TO COLLABORATE ON ATRIAL FIBRILLATION CLINICAL TRIAL FOR GENCARO TM Patients in Novel Clinical Trial Will Have Cardiac Rh
Vice President of Investor Relations AND MEDTRONIC TO COLLABORATE ON ATRIAL FIBRILLATION CLINICAL TRIAL FOR GENCAROTM Patients in Novel Clinical Trial Will Have Cardiac Rhythms Continuously Monitored With Implanted Medtronic Devices Broomfield, CO, April 22, 2013 ARCA biopha
Read more →ORKAChristopher D. Ozeroff Senior Vice President and General Counsel 720.940.2100 UNMET MEDICAL NEED IN TREATMENT OF HEART FAILURE PATIENTS WITH ATRIAL FIBRILLATION HIGHLIGHTED IN ARTICLES IN INAUGURAL ISSUE OF JACC
Christopher D. Ozeroff Senior Vice President and General Counsel NEED IN TREATMENT OF HEART FAILURE PATIENTS WITH ATRIAL FIBRILLATION HIGHLIGHTED IN ARTICLES IN INAUGURAL ISSUE OF JACC: HEART FAILURE Meta-Analysis Suggests Currently Approved Beta-Blockers Have Little or No
Read more →ORKAChristopher D. Ozeroff Senior Vice President and General Counsel 720.940.2100 NEW ADAPTIVE PHASE 3 TRIAL PLANNED FOR GENCARO TM IN ATRIAL FIBRILLATION Broomfield, CO
Christopher D. Ozeroff Senior Vice President and General Counsel NEW ADAPTIVE PHASE 3 TRIAL PLANNED FOR GENCAROTM IN ATRIAL FIBRILLATION Broomfield, CO, January 29, 2013 ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company developing genetically-targeted therapie
Read more →ORKAChristopher D. Ozeroff Senior Vice President and General Counsel 720.940.2100 GENCARO TM EFFECT ON REDUCING VENTRICULAR ARRHYTHMIAS PAPER PUBLISHED IN CIRCULATION: ARRHYTHMIA AND ELECTROPHYSIOLOGY Broomfield, CO
Christopher D. Ozeroff Senior Vice President and General Counsel GENCAROTM EFFECT ON REDUCING VENTRICULAR ARRHYTHMIAS PAPER PUBLISHED IN CIRCULATION: ARRHYTHMIA AND Broomfield, CO, January 3, 2013 ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company developing g
Read more →ORKAChristopher D. Ozeroff Senior Vice President and General Counsel 720.940.2100 GENCARO TM CARDIOVASCULAR EFFECT ON PATIENTS WITH ATRIAL FIBRILLATION PAPER PUBLISHED IN EUROPEAN JOURNAL OF HEART FAILURE Broomfield
Christopher D. Ozeroff Senior Vice President and General Counsel GENCAROTM CARDIOVASCULAR EFFECT ON PATIENTS WITH ATRIAL FIBRILLATION PAPER PUBLISHED IN EUROPEAN JOURNAL OF HEART Broomfield, CO, December 12, 2012 ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical compa
Read more →ORKADerek Cole Vice President, Investor Relations & Corporate Communications 720.940.2163 derek.cole@arcabiopharma.com ARCA ANNOUNCES DEATH OF BOARD CHAIR RICHARD B. BREWER, TRAILBLAZING BIOTECHNOLOGY INDUSTRY VETER
Vice President, Investor Relations & Corporate Communications derek.cole@arcabiopharma.com ARCA ANNOUNCES DEATH OF BOARD CHAIR RICHARD B. BREWER, BIOTECHNOLOGY INDUSTRY VETERAN AND PATIENT Broomfield, CO, August 16, 2012 ARCA biopharma, Inc. (Nasdaq: ABIO), today announced th
Read more →ORKADerek Cole Vice President, Investor Relations & Corporate Communications 720.940.2163 derek.cole@arcabiopharma.com GENCARO TM S NOREPINEPHRINE LOWERING LIKELY CONTRIBUTES TO ITS EFFECT IN ATRIAL FIBRILLATION PRE
Vice President, Investor Relations & Corporate Communications derek.cole@arcabiopharma.com NOREPINEPHRINE LOWERING LIKELY CONTRIBUTES TO ITS EFFECT IN ATRIAL FIBRILLATION PREVENTION Data Selected for Moderated Poster Presentation at American College of Cardiology 61st Annual
Read more →ORKADerek Cole Vice President, Investor Relations & Corporate Communications 720.940.2163 derek.cole@arcabiopharma.com ARCA BIOPHARMA ANNOUNCES ADDITIONAL PATENT ISSUED FOR METHODS FOR TREATMENT WITH BUCINDOLOL BASE
Vice President, Investor Relations & Corporate Communications derek.cole@arcabiopharma.com ARCA BIOPHARMA ANNOUNCES ADDITIONAL PATENT ISSUED FOR METHODS FOR TREATMENT WITH BUCINDOLOL BASED ON GENOTYPE OF Pharmacogenetic Patents Have the Potential to Extend Drug Candidate s Pot
Read more →ORKADerek Cole Vice President, Investor Relations & Corporate Communications 720.940.2163 derek.cole@arcabiopharma.com ARCA BIOPHARMA ANNOUNCES PRIVATE PLACEMENT OF $1.75 MILLION WITH INSTITUTIONAL INVESTORS Broomfi
Vice President, Investor Relations & Corporate Communications derek.cole@arcabiopharma.com ARCA BIOPHARMA ANNOUNCES PRIVATE PLACEMENT OF $1.75 MILLION WITH INSTITUTIONAL INVESTORS Broomfield, CO, December 22, 2011 ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical compa
Read more →ORKADerek Cole Vice President, Investor Relations & Corporate Communications 720.940.2163 derek.cole@arcabiopharma.com GENCARO TM DEMONSTRATED 74% RISK REDUCTION FOR NEW ONSET ATRIAL FIBRILLATION IN HEART FAILURE PA
Vice President, Investor Relations & Corporate Communications derek.cole@arcabiopharma.com GENCAROTM DEMONSTRATED 74% RISK REDUCTION FOR NEW ONSET ATRIAL FIBRILLATION IN HEART FAILURE PATIENTS WITH GENOTYPE BELIEVED TO BE FOUND IN NEARLY 50% OF POPULATION Selected for Oral P
Read more →ORKADerek Cole Vice President, Investor Relations & Corporate Communications 720.940.2163 derek.cole@arcabiopharma.com GENCARO TM ATRIAL FIBRILLATION AND PHARMACOGENETICS PRESENTATIONS AT THE AMERICAN HEART ASSOCIAT
Vice President, Investor Relations & Corporate Communications derek.cole@arcabiopharma.com GENCAROTM ATRIAL FIBRILLATION AND PHARMACOGENETICS PRESENTATIONS AT THE AMERICAN HEART ASSOCIATION SCIENTIFIC Dr. Bristow Selected as one of Invited Speakers on Session Discussing Clini
Read more →ORKADerek Cole Vice President, Investor Relations & Corporate Communications 720.940.2163 derek.cole@arcabiopharma.com ARCA BIOPHARMA ANNOUNCES PLANNED EXPANSION OF GENCARO DEVELOPMENT TO ATRIAL FIBRILLATION Phase 3
Vice President, Investor Relations & Corporate Communications derek.cole@arcabiopharma.com ARCA BIOPHARMA ANNOUNCES PLANNED EXPANSION DEVELOPMENT TO ATRIAL FIBRILLATION Phase 3 Trial of Gencaro in Heart Failure Patients with Atrial Fibrillation Planned To Begin Enrollment i
Read more →ORKADerek Cole Vice President, Investor Relations & Corporate Communications 720.940.2163 derek.cole@arcabiopharma.com ARCA BIOPHARMA SIGNS GLOBAL RIGHTS AGREEMENT WITH LARGE PHARMA COMPANY FOR ONE OF ARCA S EARLY S
Vice President, Investor Relations & Corporate Communications derek.cole@arcabiopharma.com ARCA BIOPHARMA SIGNS GLOBAL RIGHTS AGREEMENT WITH LARGE PHARMA COMPANY FOR ONE OF ARCA S EARLY STAGE ASSETS Broomfield, CO, May 3, 2011 ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharm
Read more →ORKADerek Cole Vice President, Investor Relations & Corporate Communications 720.940.2163 derek.cole@arcabiopharma.com ARCA BIOPHARMA ANNOUNCES $3 MILLION EQUITY OFFERING Broomfield, CO
Vice President, Investor Relations & Corporate Communications derek.cole@arcabiopharma.com ARCA BIOPHARMA ANNOUNCES $3 MILLION EQUITY Broomfield, CO, April 18, 2011 ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company developing genetically-targeted therapies for
Read more →ORKADerek Cole Vice President, Investor Relations & Corporate Communications 720.940.2163 derek.cole@arcabiopharma.com ARCA BIOPHARMA LICENSES EXCLUSIVE WORLDWIDE RIGHTS TO BUCINDOLOL GENETIC MARKERS Broomfield, CO
Vice President, Investor Relations & Corporate Communications derek.cole@arcabiopharma.com ARCA BIOPHARMA LICENSES EXCLUSIVE WORLDWIDE RIGHTS TO BUCINDOLOL GENETIC MARKERS Broomfield, CO, April 15, 2011 ARCA biopharma, Inc. (Nasdaq: ABIO) today announced that it has entered
Read more →ORKADerek Cole Vice President, Investor Relations & Corporate Communications 720.940.2163 derek.cole@arcabiopharma.com ARCA BIOPHARMA AWARDED $489,000 GRANT UNDER QUALIFYING THERAPEUTIC DISCOVERY PROJECT ARCA is dev
Vice President, Investor Relations & Corporate Communications derek.cole@arcabiopharma.com ARCA BIOPHARMA AWARDED $489,000 GRANT THERAPEUTIC DISCOVERY PROJECT ARCA is developing the first potential genetically-targeted therapy for heart failure Broomfield, CO, November 4, 2
Read more →ORKADerek Cole Vice President, Investor Relations & Corporate Communications 720.940.2163 derek.cole@arcabiopharma.com ARCA BIOPHARMA ANNOUNCES EUROPEAN PATENT ISSUED FOR TREATING HEART FAILURE PATIENTS WITH BUCINDO
Vice President, Investor Relations & Corporate Communications derek.cole@arcabiopharma.com ARCA BIOPHARMA ANNOUNCES EUROPEAN PATENT ISSUED FOR TREATING HEART FAILURE PATIENTS WITH BUCINDOLOL BASED ON GENETIC Patents Issued in United States, Europe and Russia Broomfield, CO,
Read more →ORKADerek Cole Vice President, Investor Relations & Corporate Communications 720.940.2163 derek.cole@arcabiopharma.com ARCA ANNOUNCES SPECIAL PROTOCOL ASSESSMENT AGREEMENT WITH FDA FOR BUCINDOLOL DEVELOPMENT IN GENO
Vice President, Investor Relations & Corporate Communications derek.cole@arcabiopharma.com ARCA ANNOUNCES SPECIAL PROTOCOL ASSESSMENT AGREEMENT WITH FDA FOR BUCINDOLOL DEVELOPMENT IN GENOTYPE-DEFINED HEART Broomfield, CO, May 17, 2010 ARCA biopharma, Inc. (Nasdaq: ABIO) toda
Read more →ORKADerek Cole Vice President, Investor Relations & Corporate Communications 720.940.2163 derek.cole@arcabiopharma.com ARCA Regains NASDAQ Listing Compliance Broomfield, CO
Vice President, Investor Relations & Corporate Communications derek.cole@arcabiopharma.com ARCA Regains NASDAQ Listing Compliance Broomfield, CO, May 13, 2010 ARCA biopharma, Inc. (NASDAQ: ABIO), a biopharmaceutical company developing genetically targeted therapies for heart
Read more →ORKADerek Cole Vice President, Investor Relations & Corporate Communications 720.940.2163 derek.cole@arcabiopharma.com ARCA BIOPHARMA RAISES $6.8 MILLION IN FIRST QUARTER OF 2010 THROUGH AT-THE-MARKET OFFERING OF CO
Vice President, Investor Relations & Corporate Communications derek.cole@arcabiopharma.com ARCA BIOPHARMA RAISES $6.8 MILLION IN FIRST QUARTER OF 2010 THROUGH AT-THE-MARKET OFFERING OF COMMON STOCK April 1, 2010 ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company
Read more →ORKADerek Cole Vice President, Investor Relations & Corporate Communications 720.940.2163 derek.cole@arcabiopharma.com ARCA BIOPHARMA ANNOUNCES PATENT ISSUED FOR TREATING HEART FAILURE PATIENTS WITH BUCINDOLOL BASED
Vice President, Investor Relations & Corporate Communications derek.cole@arcabiopharma.com ARCA BIOPHARMA ANNOUNCES PATENT ISSUED FOR TREATING HEART FAILURE PATIENTS WITH BUCINDOLOL BASED ON GENETIC TESTING Revised Request for FDA Special Protocol Assessment for GencaroTM Dev
Read more →ORKADerek Cole Vice President, Investor Relations & Corporate Communications 720.940.2163 derek.cole@arcabiopharma.com ARCA Announces Receipt of NASDAQ Notice per NASDAQ Rule 5810(b) Broomfield, CO
Vice President, Investor Relations & Corporate Communications derek.cole@arcabiopharma.com ARCA Announces Receipt of NASDAQ Notice per NASDAQ Rule 5810(b) Broomfield, CO, March 17, 2010 ARCA biopharma, Inc. (NASDAQ: ABIO), a biopharmaceutical company developing genetically tar
Read more →ORKADerek Cole Vice President, Investor Relations & Corporate Communications 720.940.2163 derek.cole@arcabiopharma.com ARCA ANNOUNCES PUBLICATION OF BUCINDOLOL DATA IN CIRCULATION: HEART FAILURE Data from the clinic
Vice President, Investor Relations & Corporate Communications derek.cole@arcabiopharma.com ARCA ANNOUNCES PUBLICATION OF BUCINDOLOL DATA IN CIRCULATION: clinical study BEST indicate that in the study norepinephrine lowering and clinical therapeutic responses to bucindolol we
Read more →ORKADerek Cole Vice President, Investor Relations & Corporate Communications 720.940.2163 derek.cole@arcabiopharma.com ARCA BIOPHARMA RECEIVES NOTICE OF ALLOWANCE FOR PATENT FOR TREATING HEART FAILURE PATIENTS WITH
Vice President, Investor Relations & Corporate Communications derek.cole@arcabiopharma.com ARCA BIOPHARMA RECEIVES NOTICE OF ALLOWANCE FOR PATENT FOR TREATING HEART FAILURE PATIENTS WITH BUCINDOLOL BASED ON Broomfield, CO, January 11, 2010 ARCA biopharma, Inc. (Nasdaq: ABIO),
Read more →ORKADerek Cole Vice President, Investor Relations & Corporate Communications 720.940.2163 derek.cole@arcabiopharma.com ARCA ANNOUNCES SUBMISSION OF A REQUEST FOR SPECIAL PROTOCOL ASSESSMENT FOR GENCARO TM DEVELOPMEN
Vice President, Investor Relations & Corporate Communications derek.cole@arcabiopharma.com ARCA ANNOUNCES SUBMISSION OF A REQUEST FOR SPECIAL PROTOCOL ASSESSMENT FOR GENCAROTM DEVELOPMENT IN GENOTYPE-DEFINED HEART FAILURE POPULATION December 22, 2009 ARCA biopharma, Inc. (Na
Read more →ORKADerek Cole Vice President, Investor Relations & Corporate Communications 720.940.2163 derek.cole@arcabiopharma.com ARCA RECEIVES FDA FAST TRACK DESIGNATION FOR GENCARO TM DEVELOPMENT IN GENOTYPE-DEFINED HEART FA
Vice President, Investor Relations & Corporate Communications derek.cole@arcabiopharma.com ARCA RECEIVES FDA FAST TRACK DESIGNATION FOR GENCAROTM DEVELOPMENT IN GENOTYPE-DEFINED HEART FAILURE POPULATION Broomfield, CO, November 23, 2009 ARCA biopharma, Inc. (Nasdaq: ABIO) tod
Read more →ORKADerek Cole Vice President, Investor Relations & Corporate Communications 720.940.2163 derek.cole@arcabiopharma.com ARCA BIOPHARMA ANNOUNCES CORPORATE AND GENCARO TM DEVELOPMENT UPDATE Broomfield, CO
Vice President, Investor Relations & Corporate Communications derek.cole@arcabiopharma.com ARCA BIOPHARMA ANNOUNCES CORPORATE AND GENCAROTM Broomfield, CO, November 16, 2009 ARCA biopharma, Inc. (Nasdaq: ABIO) today announced its planned next steps in response to the May 29,
Read more →ORKADerek Cole Vice President, Investor Relations & Corporate Communications 720.940.2163 derek.cole@arcabiopharma.com ARCA BIOPHARMA ANNOUNCES CHANGES TO MANAGEMENT TEAM REFLECTING CHANGE IN COMMERCIAL STRATEGY Bro
Vice President, Investor Relations & Corporate Communications derek.cole@arcabiopharma.com ARCA BIOPHARMA ANNOUNCES CHANGES TO MANAGEMENT TEAM REFLECTING CHANGE IN COMMERCIAL STRATEGY Broomfield, CO, July 1, 2009 ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical compan
Read more →ORKADerek Cole Vice President, Investor Relations & Corporate Communications 720.940.2163 derek.cole@arcabiopharma.com ARCA BIOPHARMA RECEIVES COMPLETE RESPONSE LETTER FROM FDA ON THE GENCARO TM NDA Broomfield, CO
Vice President, Investor Relations & Corporate Communications derek.cole@arcabiopharma.com ARCA BIOPHARMA RECEIVES COMPLETE RESPONSE LETTER FROM FDA ON THE GENCAROTM NDA Broomfield, CO, June 1, 2009 ARCA biopharma, Inc. (Nasdaq: ABIO) announced today that it received a Complet
Read more →ORKADerek Cole Vice President, Investor Relations & Corporate Communications 720.940.2163 derek.cole@arcabiopharma.com ARCA biopharma Appoints Kathryn Falberg as Chief Financial Officer and Chief Operating Officer B
Vice President, Investor Relations & Corporate Communications derek.cole@arcabiopharma.com ARCA biopharma Appoints Kathryn Falberg as Chief Financial Officer and Chief Operating Officer February 25, 2009 ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company developi
Read more →Competitive Position
How ORKA ranks across every disease it competes inCompetitive Position is a premium feature
See how ORKA ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial